The FDA's 2024 approval of the Farapulse system covered patients with paroxysmal atrial fibrillation. Now, however, the technology is officially approved for patients with more persistent symptoms. 

Researchers explored more than 52 years of data, highlighting several key trends in the Journal of the American Heart Association.

While Kardium raised $250 million in an oversubscribed funding round, Field Medical raised $35 million. Both companies are focused on designing and developing new pulsed field ablation technologies to help treat challenging arrhythmias. 

The Heart Rhythm Society and its new advocacy arm plan on pushing CMS to include certain policy improvements in the 2026 MPFS.

Clinical guidelines already recommend that these procedures be performed together when applicable. However, researchers noted, it is still not terribly common among today’s surgeons. 

The Varipulse PFA platform originally gained FDA approval in 2024. According to Johnson & Johnson MedTech, this update was put in place to help the technology provide better patient outcomes going forward.

Philips has launched a new 'AI Marketplace' that expands access to third-party diagnostic tools. The company's goal is to put a variety of offerings into one convenient location for clinicians.